- Bupa Platinum consultant
- Fee assured
- Awaiting verification
- Open Referral network
- Lower GI
- Upper GI
- Video and telephone consultations
I am a consultant clinical oncologist at the Mount Vernon Cancer Centre. My interests are in the management of upper and lower gastrointestinal malignancies and general/acute oncology. I am able to advise on the treatment for unknown primary cancers and have an interest in both radiotherapy, including stereotactic radiotherapy with cyberknife, and chemotherapy.
I am actively involved with research and recruit and manage patients enrolled in clinical trials. I have several first name publications in peer reviewed journals and have presented on multiple occasions at international conferences.
I qualified from Imperial College London and completed my junior medical training at the Hammersmith and Charing Cross Hospitals. I have completed 7 years of specialist training in north London at Mount Vernon, North Middlesex, Imperial and UCLH. This also included a fellowship in radiotherapy at the Royal Marsden Hospital and a postgraduate Masters degree in Oncology at the Institute of Cancer Research. I am a Member of the Royal College of Physicians and a Fellow of the Royal College of Radiologists. I am also an examiner for the Final Fellowship examination and am very involved in education and specialist training within London.
I live with my family in London, am a keen sports enthusiast and and I am also fluent in Gujarati.
Areas of interest
General Oncology; Intensity Modulated Radiotherapy; Stereotactic Body Radiotherapy, Cyberknife
Current NHS consultant posts held
Consultant Clinical Oncologist
Mount Vernon Cancer Centre
East & North Hertfordshire NHS Trust
Colorectal, Oesophago-gastric and Hepatibiliary malignancies
Charity work in East Africa
Sport, including football, Formula One, Cricket
(Additional) Languages spoken
- Gujarati - Fluent
Whole Brain Radiotherapy for cerebral metastases in advanced non-small cell lung cancer; does it make a difference? An analysis of factors influencing outcomes.
Bhuva N, Buckley H, Ranger A, Goyal N, Koay S, Singer J, Gupta N, Anand G
European Journal of Palliative Care Medicine, Vol. 22 No 5, 214-218
Use of Raltitrexed as an alternative to 5-fluorouracil and Capecitabine in cancer patients with cardiac history.
Kelly C, Bhuva N, Harrison M, Buckley A, Saunders M
European Journal of Cancer, July 2013, Vol. 49 No. 10, 2303-2310
To PET or not to PET? That is the question. Staging in Anal Cancer.
Bhuva N, Glynne-Jones R, Sonoda L, Wong W-L, Harrison M
Annals of Oncology, January 2012, Vol. 23 No. 8, 2078-82
Intraductal tubulopapillary neoplasm of the pancreas as a radiation induced malignancy â€“ a case report.
Bhuva N, Spalding D, Wasan H, Stamp G, Harrison M
BMJ Case Reports, December 2011; Epub doi:10.1136/bcr.09.2011.4777
Living with and beyond cancer: New Challenges
Bhuva N, Li SP, Maher EJ
Topics in Cancer Survivorship edited by R Mohan
January 2012 ISBN 978-953-307-894-6
- Bachelor of Science Imperial College, London 2003
- Bachelor of Medicine, Bachelor of Surgery Imperial College, London 2005
- Master of Science Institute of Cancer Research 2013
- Cyberknife System Product Training - Stereotactic Radiotherapy Accuray 2017
Reference number 6129823
Details of entry to specialist register
- Clinical Oncology , 2016
Affiliations / memberships
Fellow of the Royal College of Radiologists
Member of the Royal College of Physicians
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (>50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)
Preparation for complex radiotherapy with Intensity Modulated Radiotherapy (IMRT) - (5-50)
Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)
- Show All (8 )...